Module 1 – Why Device Care Matters
Part of the Purus Lumina Device Care Education Programme
This module establishes why device care is a clinical requirement, not a preference.
The medicine is prescribed. The device is not.
Prescribed botanical medicine in the United Kingdom is prescribed by a GMC-registered specialist. The device used to consume it is sourced separately by the patient. That distinction is not administrative. It has clinical consequences.
The device sits outside the clinical pathway. No prescriber checks it. No clinic maintains it. No guidance exists for how it should be cleaned, stored, or replaced. The patient is left to manage a medical delivery instrument without a documented standard of care.
This curriculum exists because that standard was absent. It documents what should have been in place from the outset.
What is being consumed
Cannabis-Based Products for Medicinal use (CBPMs) are prescribed across multiple consumption routes — vaporisation, oral, sublingual, and topical. Each route has its own considerations. This curriculum addresses the vaporisation pathway, which is the most widely used route in the UK clinical pathway and the one that introduces the greatest device-related variable into the patient's medicine.
A CBPM consumed by vaporisation is, in most cases, a dried botanical preparation. No tobacco. No cutting agents. No additives. The prescription is the CBPM, and the CBPM alone. Research into the vaporisation of botanical material consistently identifies two primary variables affecting what is inhaled: temperature and device cleanliness. At the correct temperature, through a clean device, vaporisation delivers cannabinoids and terpenes. Through a contaminated device, it delivers those compounds alongside everything that has accumulated since the last clean.
Where a CBPM is vaporised, the device is part of the delivery system. It is not peripheral to the prescription. It is the instrument through which the prescription is administered.
What an uncleaned device does to a prescription
Every session leaves residue. Cannabinoid oils, botanical matter, and moisture accumulate in the chamber, airways, mouthpiece, screens, seals, and every removable component. Over time, and without intervention, this residue:
- Degrades at high temperatures, producing combustion byproducts that were not part of the original prescription
- Creates conditions for microbial growth — bacteria and mould in a warm, moist, organic environment
- Restricts airflow, altering the temperature profile and vapour density the device was calibrated to deliver
- Contaminates each new dose with residue from previous sessions
- Accelerates wear on heating elements, screens, seals, and O-rings, shortening device lifespan and increasing the cost of replacement
None of this is visible during normal use. The device continues to function. The degradation is silent and cumulative.
Why this is a clinical variable, not a hygiene preference
A GMC-registered specialist selects a specific strain, terpene profile, and cannabinoid ratio for a documented therapeutic reason. That precision is undermined the moment the delivery device is compromised.
A contaminated device does not deliver the prescription. It delivers the prescription combined with everything that has accumulated since the last clean. Dose consistency, onset time, and therapeutic effect are all affected by device condition. This is not a matter of personal preference or domestic habit. It is a matter of whether the medicine reaches the patient in the form it was prescribed.
The MHRA defines off-label use of a medical device as any use that departs from the manufacturer's instructions. The classified medical devices used to administer CBPMs are supplied with explicit cleaning and maintenance instructions. Failure to follow those instructions constitutes off-label use under UK medical device regulations. Off-label use is at the patient's own risk.
The standard that should apply
Any instrument used to administer a prescribed medicine should be maintained to a standard consistent with that use. In clinical and hospital settings, this principle is foundational and non-negotiable. For patients managing their own devices at home, that standard has never been formally defined.
The MHRA, alongside the United States Food and Drug Administration and Health Canada, has co-authored international transparency principles for medical devices. Those principles state that transparency must support device maintenance and the detection of errors or performance degradation. Device maintenance is not a peripheral consideration — it is named explicitly in a document co-signed by the UK's own medicines regulator as a transparency obligation owed to patients.
No resource within the MHRA's cannabis-based products for medicinal use information estate addresses the maintenance of the classified medical devices through which the majority of CBPMs are administered. The international standard exists. The patient-facing guidance does not.
This curriculum applies the same rigour to device care that governs the medicine itself. It is written for patients, referenced by clinicians, and submitted to regulatory bodies as a documented contribution to a gap that has existed since prescribed botanical medicine was legalised in the United Kingdom in 2018.
The responsibility that extends beyond the manufacturer
Under the Medicines and Medical Devices Act 2021, the MHRA's enforcement powers apply not only to manufacturers of medical devices but to all parties in the marketing and supply chain. Clinics that supply classified medical devices to patients occupy a position within that supply chain. Whether the absence of device care guidance at the point of supply constitutes a breach of the UK Medical Devices Regulations 2002 has not been tested. It is a question that this curriculum exists, in part, to raise.
Patients should be aware that the obligation to maintain their device correctly rests with them — and that the regulatory framework governing that obligation is more extensive than any clinic has communicated.
This module is the foundation of the curriculum. It establishes the argument. Every subsequent module builds on what is documented here.
In plain terms
Your medicine was prescribed by a GMC-registered specialist. The device you use to take it was not. Nobody has told you how to look after it. This curriculum does.
Your medicine is a botanical preparation — nothing added, nothing mixed in. A clean device delivers it as prescribed. A dirty device does not.
Your device looks fine. It works. But what you are inhaling is no longer just your prescription — it is your prescription plus weeks or months of accumulated residue. You cannot see it. You are inhaling it.
Your GMC-registered specialist prescribed something specific. A dirty device means you are not getting it. Device care is part of taking your medicine correctly.
Under UK medical device regulations, using your device in a way that departs from the manufacturer's instructions — including failing to clean it as instructed — is classified as off-label use. That is not a technicality. It is the legal position.
There has never been a guide for how to look after your dry herb device. Until now. What follows is that guide.
Notice of Intent
This curriculum has been submitted to the MHRA, Home Office, NHS England, NICE, the Care Quality Commission, relevant parliamentary and clinical bodies, and device manufacturers operating within the UK prescribed medicine pathway, as a formal educational contribution to a documented gap in patient care. It is published in perpetuity as a matter of public record. Purus Lumina reserves all rights to the curriculum structure, content, and methodology.
Get the Solution
The Purus Lumina Device Purification Solution is purpose-formulated for the components, seals, and materials of dry herb devices. 99.9% pharmaceutical-grade. UK-made. No plastic. No compromise.
Available in 250ml, 500ml, and 1L — in recyclable aluminium with a silver screw cap.
Isopropanol is available in three common grades — 70%, 91%, and 99.9%. Only 99.9% pharmaceutical-grade is the correct standard for medical device care. 70% and 91% contain water — affecting evaporation rate and leaving residue in device components.
A purpose-formulated solution is not a preference. It is the correct standard.
Get the Device Purification Solution →
Continue to Module 2 – The Cleaning Protocol →
← Return to the Device Care Education hub
Module 1 is the foundational document of the Purus Lumina Device Care Curriculum — the world's first documented device care education programme for patients prescribed botanical medicine. Published as a matter of public record. Preserved in perpetuity.
This module was published on 27 June 2026 and exists in perpetuity as part of the Purus Lumina Device Care Curriculum — the world's first documented device care education programme for patients prescribed botanical medicine. It will not be removed.
Glenn Hailes · Director · Purus Lumina Ltd · 3rd Floor, 86–90 Paul Street · London EC2A 4NE · United Kingdom · Registered in England and Wales